Genomic Characterization of Metastatic Castration Resistant Prostate Cancer

Description

Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant prostate cancer (mCRPC). This study is made available on AWS via the NIH STRIDES Initiative.

Update Frequency

Genomic Data Commons (GDC) is source of truth for this dataset; GDC offers monthly data releases, although this dataset may not be updated at every release.

License

NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies

Documentation

https://isb-cancer-genomics-cloud.readthedocs.io/en/latest/sections/data/WCDT_about.html

Managed By

See all datasets managed by Center for Translational Data Science at The University of Chicago.

Contact

support@nci-gdc.datacommons.io

How to Cite

Genomic Characterization of Metastatic Castration Resistant Prostate Cancer was accessed on DATE from https://registry.opendata.aws/mcrpc. dbGaP accession phs001648.v2.p1

Usage Examples

Tools & Applications

• Genomic Data Commons by National Cancer Institute
  

Publications

• Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience by Swayamjeet Satapathy, Chandan K Das, et al.